title: [Efficacy of the energy-modifier cytoflavin in the treatment of patients with hypertensive encephalopathy].
abstract: OBJECTIVE
  To evaluate the efficacy of cytoflavin in the treatment of patients with hypertensive encephalopathy (HE).
  
  
  METHODS
  One hundred and forty patients aged 39 to 73 years, diagnosed with HE, were examined and randomized to 2 groups. A study group (n = 74) received cytoflavin in a dose of 2 tablets b.i.d. on days 1 to 25 days inclusive during standard basic therapy. A comparison group (n = 66 persons) had standard basic therapy only. A control group consisted of 30 apparently healthy individuals. The investigators studied the frequency of headache, dizziness, and other complaints and the intensity of cephalalgic syndrome, by using a visual analog scale, the quality of life by the Medical Outcomes Study 36-Item Short-Form Health Survey (MOS SF-36) questionnaire, that of sleep by the subjective sleep characteristics questionnaire elaborated at the Moscow City Somnological Center, the level of asthenia by a subjective asthenia rating scale (Multidimensional Fatigue Inventory (MFI-20), and autonomic status, by applying objective and subjective scales on days 1 and 25 of therapy.
  
  
  RESULTS
  The study has shown that cytoflavin used in the above dose for 25 days reduces the frequency and magnitude of complaints of headache, dizziness, "venous" complaints, the degree of autonomic and asthenic disorders, and impairments in the quality of sleep and life in the patients with HE at all disease stages. A stepwise discriminant analysis has indicated that the degree of cephalgic syndrome, and autonomic disorders, and worse sleep quality are the most effective points for using the energy-modifier cytoflavin.
  
  
  CONCLUSIONS
  HE treatment based on the current pathogenetic principles may have a preventive impact on the development of HE or slow down the rate of its progression.
authors.forename: L A
authors.initials: LA
authors.lastname: Belova
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Kolotik-Kameneva
authors.forename: V V
authors.initials: VV
authors.lastname: Mashin
authors.forename: L V
authors.initials: LV
authors.lastname: Saprygina
authors.forename: E V
authors.initials: EV
authors.lastname: Mashin
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D016903:Drug Monitoring; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D005486:Flavin Mononucleotide / Q000008:administration & dosage*; D006261:Headache / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology; D007290:Inosine Diphosphate / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009449:Neurocirculatory Asthenia / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D009536:Niacinamide / Q000008:administration & dosage*; D010147:Pain Measurement / Q000379:methods; D017286:Polysomnography; D011788:Quality of Life; D012720:Severity of Illness Index; D012893:Sleep Wake Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D013386:Succinates / Q000008:administration & dosage*; D016896:Treatment Outcome; D064232:Visual Analog Scale; D014803:Vitamin B Complex / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D013386:Succinates; C507879:cytoflavin; D014803:Vitamin B Complex; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate